15.50

1.27% -0.20

Arrowhead Pharmaceuticals Inc (ARWR)

Overview News Price History Option Chain Financials Why ARWR Down? Discussions Forecast Stock Split

Arrowhead Pharmaceuticals Inc stock is traded at $15.50, with a volume of 2.04M. It is down -1.27% in the last 24 hours and down -1.34% over the past month. Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Previous Close:

$15.70

Open:

$15.5

24h Volume:

2.04M

Relative Volume:

1.12

Market Cap:

$2.34B

Revenue:

$181.74M

Net Income/Loss:

$-143.97M

P/E Ratio:

-11.15

EPS:

-1.39

Net Cash Flow:

$9.60M

1W Performance:

-8.66%

1M Performance:

-1.34%

6M Performance:

-30.40%

1Y Performance:

-38.25%

1-Day Range:

$15.19

$16.06

1-Week Range:

$15.19

$17.49

52-Week Range:

$9.57

$30.41

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name

Arrowhead Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (662)

Phone

626-696-4702

Address

177 E COLORADO BLVD, PASADENA, CA

Employee

609

Twitter

@ArrowheadPharma

Next Earnings Date

2025-02-10

Latest SEC Filings

ARWR's Discussions on Twitter

Compare ARWR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARWR Arrowhead Pharmaceuticals Inc	15.50	2.34B	181.74M	-143.97M	9.60M	-1.39
VRTX Vertex Pharmaceuticals Inc	441.99	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	508.86	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	308.71	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	540.71	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	254.09	28.51B	3.81B	-644.79M	-669.77M	-6.24

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-24	Initiated	Goldman	Neutral
Dec-04-23	Initiated	BofA Securities	Buy
Sep-19-23	Initiated	Citigroup	Neutral
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform
Jan-19-22	Resumed	Goldman	Buy
Aug-06-21	Reiterated	Chardan Capital Markets	Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	UBS	Buy
Nov-19-20	Initiated	Citigroup	Buy
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-08-20	Upgrade	Oppenheimer	Perform → Outperform
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform
Mar-17-20	Initiated	Goldman	Neutral
Jan-21-20	Initiated	SVB Leerink	Underperform
Dec-13-19	Initiated	Oppenheimer	Perform
Nov-29-19	Reiterated	Chardan Capital Markets	Buy
Nov-27-19	Reiterated	B. Riley FBR	Buy
Nov-25-19	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-24-19	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-22-19	Reiterated	Chardan Capital Markets	Buy
Oct-03-19	Initiated	Robert W. Baird	Outperform
Sep-07-18	Upgrade	B. Riley FBR	Neutral → Buy
Sep-06-18	Reiterated	Chardan Capital Markets	Buy
Aug-08-18	Reiterated	Cantor Fitzgerald	Overweight
Jul-02-18	Reiterated	Chardan Capital Markets	Buy

View All

Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News

Jun 12, 2025

Where are the Opportunities in (ARWR) - news.stocktradersdaily.com

Jun 12, 2025

Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail

Jun 12, 2025

GAMMA Investing LLC Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 12, 2025

Cantor Fitzgerald Weighs in on ARWR FY2026 Earnings - Defense World

Jun 12, 2025

Jun 10, 2025

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 10, 2025

Jun 09, 2025

Arrowhead Pharmaceuticals at Goldman Sachs Conference: Strategic Launch Plans By Investing.com - Investing.com Canada

Jun 09, 2025

Jun 08, 2025

California State Teachers Retirement System Reduces Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World

Jun 08, 2025

Jun 07, 2025

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to “Buy” at Wall Street Zen - Defense World

Jun 07, 2025

Jun 05, 2025

Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - Insider Monkey

Jun 05, 2025

Jun 04, 2025

Arrowhead at Jefferies Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada

Jun 04, 2025

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses' - Benzinga

Jun 04, 2025

Jun 02, 2025

Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus

Jun 02, 2025